|
Myocardial Infarction
|
0.490 |
SusceptibilityMutation
|
disease |
CLINVAR |
|
|
|
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects.
|
16285995 |
2005 |
|
Chlamydia pneumoniae Infections
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Chlamydia pneumoniae infection enhances lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression on human endothelial cells.
|
16790013 |
2006 |
|
Carpal Tunnel Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CTS significantly attenuated atherosclerotic plaque formation and enhanced plaque stability in ApoE(-/-) mice by inhibiting the expression of lectin-like oxLDL receptor-1 (LOX-1) and MMP-9, as well as inhibiting reactive oxygen species (ROS) generation and NF-κB activation.
|
25572313 |
2015 |
|
Cardiomyopathies
|
0.310 |
Biomarker
|
group |
BEFREE |
Cardiomyopathy was induced by a single intraperitoneal injection of DOX into wild-type (WT) mice and LOX-1 knockout (KO) mice.
|
27195769 |
2016 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Arthritis was induced in the right knees of C57Bl/6 wild-type (WT) and LOX-1 KO mice via zymosan injection.Saline was injected in the left knees.
|
29569871 |
2018 |
|
Sleep Apnea, Central
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CsA significantly increased expression of the LOX1 receptor in naïve macrophages, downregulated expression of CD36 and SR-A1 in the M1 subpopulation and upregulated expression of all evaluated scavenger receptors.
|
31227843 |
2019 |
|
Cockayne Syndrome, Type I
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CsA significantly increased expression of the LOX1 receptor in naïve macrophages, downregulated expression of CD36 and SR-A1 in the M1 subpopulation and upregulated expression of all evaluated scavenger receptors.
|
31227843 |
2019 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis.
|
12163130 |
2002 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LOX-1 is upregulated in aortas of diabetic rats and thus may contribute to the pathogenesis of human diabetic atherosclerosis.
|
15001526 |
2004 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
LOX-1 is upregulated in aortas of diabetic rats and thus may contribute to the pathogenesis of human diabetic atherosclerosis.
|
15001526 |
2004 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LOX-1 is upregulated in aortas of diabetic rats and thus may contribute to the pathogenesis of human diabetic atherosclerosis.
|
15001526 |
2004 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
OLR1 is a good candidate gene, due to its function in lipid metabolism pathways, other components of which have been previously implicated as risk factors for AD.
|
15276231 |
2004 |
|
Acute Coronary Syndrome
|
0.060 |
Biomarker
|
disease |
LHGDN |
Lectin-like oxidized LDL receptor-1 (LOX-1) appears to play crucial roles in the pathogenesis of atherosclerotic plaque rupture and ACS onset.
|
16061745 |
2005 |
|
Vascular lesions
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
LOX-1 expression is elevated within vascular lesions and a serum soluble LOX-1 fragment appears diagnostic of patients with acute coronary syndromes.
|
18092947 |
2008 |
|
Acute Coronary Syndrome
|
0.060 |
Biomarker
|
disease |
BEFREE |
LOX-1 expression is elevated within vascular lesions and a serum soluble LOX-1 fragment appears diagnostic of patients with acute coronary syndromes.
|
18092947 |
2008 |
|
Vascular Diseases
|
0.080 |
Biomarker
|
group |
BEFREE |
LOX-1 is increasingly viewed as a vascular disease biomarker and a potential therapeutic target in heart attack and stroke prevention.
|
18092947 |
2008 |
|
Myocardial Infarction
|
0.490 |
Biomarker
|
disease |
BEFREE |
LOX-1 is increasingly viewed as a vascular disease biomarker and a potential therapeutic target in heart attack and stroke prevention.
|
18092947 |
2008 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
LOX-1 is increasingly viewed as a vascular disease biomarker and a potential therapeutic target in heart attack and stroke prevention.
|
18092947 |
2008 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
LOX-1 polymorphisms could influence statin effectiveness in CAD prevention by induction of sensitivity to antithrombotic mechanisms such as antiplatelet activity.
|
18173546 |
2008 |
|
Hyperlipidemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
LOX-1-mediated uptake of RLPs may thus play important roles in atherogenesis by inducing LOX-1 expression and VSMC migration especially in the settings of postprandial hyperlipidemia, diabetes and metabolic syndrome.
|
18282574 |
2008 |
|
Metabolic Syndrome X
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
LOX-1-mediated uptake of RLPs may thus play important roles in atherogenesis by inducing LOX-1 expression and VSMC migration especially in the settings of postprandial hyperlipidemia, diabetes and metabolic syndrome.
|
18282574 |
2008 |
|
Diabetes
|
0.050 |
Biomarker
|
disease |
BEFREE |
LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes.
|
18322020 |
2008 |
|
Diabetes Mellitus
|
0.050 |
Biomarker
|
group |
BEFREE |
LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes.
|
18322020 |
2008 |
|
Endothelial dysfunction
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LOX-1 has been demonstrated to contribute not only to endothelial dysfunction, but also to atherosclerotic-plaque formation, myocardial infarction and intimal thickening after balloon injury.
|
19801851 |
2009 |